Toxicology Report

Science-backed PDE/ADE, OEL & OEB derivation by certified toxicologists with ex-agency experts -

Progesterone

What is Progesterone?

CAS No: 57-83-0

Progesterone belongs to the steroid hormone class and exerts its biological effects through high-affinity binding to specific nuclear receptor subtypes that act as ligand-activated transcription factors upon steroid occupancy. Receptor-ligand complex formation triggers dimerisation, nuclear translocation, and sequence-specific DNA binding at hormone response elements, modulating the transcription of gene networks that control critical physiological homeostasis mechanisms.

The intraspecies uncertainty factor F2 for Progesterone covers the range of pharmacokinetic and pharmacodynamic variability within the human population, ensuring the derived PDE is protective for sensitive subgroups including paediatric patients with immature CYP450 activity, elderly patients with reduced hepatic and renal clearance, patients with

To derive PDE/ADE, OEL, and OEB values, Masuu Global follows a scientifically justified, risk-based toxicological assessment approach in accordance with internationally recognized guidelines and industry best practices that are widely accepted by regulatory authorities, including European Medicines Agency (EMA), Pharmaceutical Inspection Co-operation Scheme (PIC/S), and Agência Nacional de Vigilância Sanitária (ANVISA).

Request Your Assessment

Add this compound to your inquiry list and our team will follow up with full documentation, pricing, and licensing terms.

View Inquiry List →
What's included:
Full OEL derivation · ADE/PDE value · Control band assignment · All cited references · EMA / ICH Q9 compliance
9,000+
Toxicological & Exposure
Assessment Reports Delivered
70+
Subject Matter Experts
across global operations
12
In-House Ex-Agency
Toxicologists
3
Certification Bodies:
ERT · UKRT · DABT

Assessment Methodology

Masuu Global follows a scientifically justified, risk-based toxicological approach aligned with internationally recognized guidelines accepted by EMA, PIC/S, and ANVISA.

EMA – Guideline on Setting Health-Based Exposure Limits (HBELs)

Provides the framework for establishing scientifically justified PDE/ADE values for use in shared manufacturing facilities.

PIC/S – Shared Facilities and Contamination Control Guidance

Supports the application of HBEL-based approaches for cross-contamination prevention and cleaning validation.

ICH Q9 – Quality Risk Management

Provides a structured methodology for risk identification, assessment, control, communication, and review.

ICH M7 – Assessment and Control of DNA-Reactive (Mutagenic) Impurities (where applicable)

Applied for compounds with potential mutagenic or genotoxic concerns.

Risk-Based Toxicological Assessment

Comprehensive evaluation of available toxicological and pharmacological data, including NOAEL, LOAEL, BMDL, pharmacological potency, carcinogenicity, reproductive and developmental toxicity, sensitization potential, and target organ toxicity.

Weight-of-Evidence (WoE) Approach

Integration and critical review of all relevant data sources, including non-clinical studies, clinical studies, human exposure data, pharmacological information, post-marketing safety data, and structure–activity relationship (SAR/QSAR) assessments.

Report Preparation Process

Every assessment moves through a rigorous five-stage workflow — from data gathering to regulatory-ready delivery.

01

Comprehensive Data Review

Assessment of pharmacology, toxicology, clinical data, literature, and available regulatory information.

02

Scientific Evaluation

Identification of critical endpoints and selection of appropriate exposure limits.

03

PDE / HBEL Derivation

Transparent and scientifically justified calculations aligned with global toxicological principles.

04

Ex-Agency Expert Review (Our Differentiator)

Reports are reviewed with an ex-agency perspective, bringing regulatory expectations, inspection readiness, and practical implementation into every assessment.

05

Final Report Delivery

Regulatory-ready reports with scientific rationale, calculations, and clear recommendations by certified toxicologists (ERT, UKRT and DABT).

Why Masuu Global?

Our ex-agency toxicologists bring a practical regulatory perspective that transforms how assessments are built, reviewed, and defended.

✓

Regulatory expectation–driven assessments aligned with how authorities actually evaluate submissions.

✓

Inspection-ready reports — scientifically defensible and audit-prepared from day one.

✓

Faster review cycles with direct decision support from certified toxicologists (ERT, UKRT, DABT).

✓

Practical implementation recommendations that translate science into actionable contamination control.

✓

Reduced internal effort — offload complex assessments without sacrificing quality or defensibility.

✓

Global reach across PDE/ADE, HBEL, OEL, OEB, cleaning validation, and impurity assessments.

Ready to request your assessment?

Add this compound to your inquiry list, or browse our full database of 3,000+ molecules.

Frequently Asked Questions

Progesterone is a steroid hormone. Its biological activity and the available toxicological evidence are relevant considerations when evaluating potential exposure during handling and manufacturing. Understanding the evidence and conditions of use helps support a documented, risk-based approach to handling. The specific conclusions should be grounded in documented evidence and the actual handling context.

A PDE or ADE sets a health-based limit on daily exposure to Progesterone from residual carryover. Manufacturers use it in cross-contamination risk assessments and cleaning validation when the compound is processed in shared equipment or facilities. Whether a report is required depends on how it is used and on applicable regulatory expectations.

An OEL report provides a scientifically supported benchmark for evaluating potential workplace exposure to Progesterone. It can inform decisions about engineering controls, containment, work practices, and exposure monitoring for relevant operations. The limit should be interpreted alongside the substance form, task-specific exposure potential, and a broader occupational health risk assessment.

A PDE or ADE addresses an acceptable daily exposure in a defined context, commonly to support assessment of residual carryover between products. An OEL addresses exposure in the workplace, often focusing on inhalation over a specified period. These values serve different purposes and should not be treated as interchangeable without a scientific justification.

A scientifically justified PDE or ADE can provide a health-based input for assessing the risk of residual Progesterone remaining on shared equipment. It may support the calculation of an appropriate carryover limit when combined with relevant product, process, and cleaning information. The final acceptance criteria must follow the applicable validated procedure and documented risk assessment.

An OEL is derived by reviewing the toxicological and occupational health evidence, identifying the critical effect, and applying a recognized assessment methodology. The final value should come with a documented rationale, clearly stated units, and the exposure duration it applies to, so it can be used confidently in workplace risk assessment.

An OEB places Progesterone in a hazard category using a defined banding framework and the available toxicological evidence. Criteria and numerical ranges differ between frameworks, so the report should identify the system used. The band then guides the level of containment and handling controls suited to the compound.

An occupational exposure band can help categorize a substance and guide proportionate containment and handling controls. It does not automatically replace a substance-specific occupational exposure limit. Whether an OEL is available and how the band is assigned depend on the evidence and the framework used. The report should clearly distinguish the purpose and limitations of each.

The assessment should be reconsidered when meaningful new toxicological data become available, the intended use or manufacturing process changes, or relevant guidance is updated. Changes in physical form, handling conditions, or exposure routes may also affect the risk assessment. A documented review helps confirm whether existing conclusions remain appropriate for the current context.

The physical form and handling conditions of Progesterone can influence how exposure may occur. For example, powder handling may create different inhalation considerations from transferring a solution, while process steps and containment also matter. The occupational assessment should use the available information about the material and actual tasks rather than assume that one form represents every scenario.

Masuu Global follows a scientifically justified, risk-based approach aligned with internationally recognized guidance accepted by regulators, including the EMA guideline on health-based exposure limits, PIC/S guidance on shared facilities and contamination control, ICH Q9 quality risk management, and ICH M7 where applicable.

Use the Request Your Assessment option on this page and add Progesterone to your inquiry list. The Masuu Global team will follow up with full documentation, pricing, and licensing terms. Mention your intended use and market so the scope of the report can be confirmed.

Book a Demo